Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Efficacy and safety of cladribine, low-dose cytarabine and venetoclax in relapsed/refractory acute myeloid leukemia: results of a pilot study ; volume:14 ; number:1 ; day:18 ; month:1 ; year:2024 ; pages:1-5 ; date:12.2024
Blood cancer journal ; 14, Heft 1 (18.1.2024), 1-5, 12.2024
- Creator
-
Li, Yan-Yan
Ge, Shuai-Shuai
Huang, Yuan-Hong
Xu, Ming-Zhu
Wan, Chao-Ling
Tan, Kai-Wen
Tao, Tao
Zhou, Hai-Xia
Xue, Sheng-Li
Dai, Hai-Ping
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-024-00982-3
- URN
-
urn:nbn:de:101:1-2024033111295745415638
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Yan-Yan
- Ge, Shuai-Shuai
- Huang, Yuan-Hong
- Xu, Ming-Zhu
- Wan, Chao-Ling
- Tan, Kai-Wen
- Tao, Tao
- Zhou, Hai-Xia
- Xue, Sheng-Li
- Dai, Hai-Ping
- SpringerLink (Online service)
Other Objects (12)
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
Management of relapsed-refractory diffuse large B cell lymphoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
Management of relapsed-refractory diffuse large B cell lymphoma
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland
Efficacy and safety of venetoclax combination therapy for relapsed/refractory acute myeloid leukemia: a systematic review and meta-analysis
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
Management of relapsed-refractory diffuse large B cell lymphoma